AstraZeneca (AZ) has announced a 7% increase in its annual dividend, showcasing confidence in its performance and cash generation. This news comes just before the company’s annual general meeting, where shareholders will vote on raising the pay for CEO Sir Pascal Soriot.
The timing of this announcement is crucial, as concerns about the UK’s competitiveness as a business destination have been growing. The FTSE 100 has underperformed compared to its global peers since the Brexit vote in 2016, leading to foreign takeovers of UK companies and a decrease in new listings on the London Stock Exchange.
Sir Pascal’s leadership at AZ has been instrumental in the company’s success. He took over in 2012 when the company was struggling, and successfully navigated challenges such as a takeover attempt by Pfizer. Under his leadership, AZ has launched successful products and played a key role in developing a COVID-19 vaccine.
The decision to raise Sir Pascal’s pay has sparked debate among shareholders and proxy voting agencies. While some argue that his new package is excessive, others believe he is underpaid compared to CEOs of US drugmakers. The vote on his pay is not just about one company but also reflects broader concerns about the UK’s business environment and competitiveness.
Ultimately, the outcome of this vote will not only impact Sir Pascal’s compensation but also shed light on how the public perceives the importance of business leadership in driving economic growth and innovation.